{"id":381705,"date":"2020-11-16T08:33:20","date_gmt":"2020-11-16T13:33:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381705"},"modified":"2020-11-16T08:33:20","modified_gmt":"2020-11-16T13:33:20","slug":"ziopharm-oncology-appoints-mary-thistle-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/","title":{"rendered":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\u2013 <em>Special Advisor and Former Chief of Staff for the Bill &amp; Melinda Gates Medical Research Institute Joins as Independent Director <\/em>\u2013<\/p>\n<p align=\"center\">\u2013<em> Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership <\/em>\u2013<\/p>\n<p align=\"center\">\u2013<em> Scott Braunstein, M.D., Steps Down from Board of Directors <\/em>\u2013<\/p>\n<p align=\"justify\">BOSTON, Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vv6yNftx4mDXHVqUmd5a5oTSvwtHMADxu0KeqGMFmVpKdXJ4aoFIWgaGd53mGebOBfNtheOOWwb1Bg7SOfUfGg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Ziopharm Oncology<\/u><\/a>, Inc. (\u201cZiopharm\u201d or \u201cthe Company\u201d) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill &amp; Melinda Gates Medical Research Institute, to the Company\u2019s Board of Directors (the \u201cBoard\u201d).<\/p>\n<p align=\"justify\">Ms. Thistle brings more than 25 years of experience in business development, strategy and operational leadership in the biotechnology sector. At the Bill &amp; Melinda Gates Medical Research Institute, she previously held the role of Chief of Staff before recently being appointed Special Advisor. Prior to joining the Bill &amp; Melinda Gates Medical Research Institute, Ms. Thistle was Chief Operating Officer of Dimension Therapeutics, where she directed multiple financing rounds (including the company\u2019s IPO), expanded the pipeline through strategic business development transactions, and led the sale of the company for a significant premium. Previously, Ms. Thistle was Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale of the company. She has also held leadership positions at ViaCell and PerkinElmer.<\/p>\n<p align=\"justify\">\u201cWe are delighted to welcome Mary to the Board,\u201d said Scott Tarriff, Chairman of the Board. \u201cMary is recognized as a strong collaborator and strategic leader, both as an executive and a director. Her extensive industry experience and business acumen will help ensure the Board effectively supports the Company\u2019s long-term strategy. Today\u2019s announcement results from a national search, which demonstrates the Board\u2019s ongoing commitment to refreshment with a diverse set of highly qualified individuals who can help take the Company through clinical and commercial success.\u201d<\/p>\n<p align=\"justify\">Ms. Thistle added, \u201cWe have an exciting opportunity with Ziopharm, as the Company has established a broad portfolio of innovative, clinical programs to treat a range of cancers and assembled a talented team to advance company-sponsored trials in each of its core programs. I am delighted to begin working with the Board, as well as with Laurence Cooper and the management team.\u201d\u00a0<\/p>\n<p align=\"justify\">Ms. Thistle began her career in finance as a Certified Public Accountant, after graduating summa cum laude with a bachelor\u2019s degree in business and accounting from the University of Massachusetts. Ms. Thistle serves on the Boards of Directors of Homology Medicines and Enterome SA.<\/p>\n<p align=\"justify\">The Company also announced today that Scott Braunstein, M.D., has resigned from the Board. \u201cOn behalf of the Board and entire Ziopharm organization, I\u2019d like to thank Scott for his many contributions and wish him the best in the future,\u201d said Scott Tarriff.<\/p>\n<p align=\"justify\">The Board consists of eight directors, including seven non-employee directors. Five directors have joined the Board in the last two years. The Board continues to actively review its composition, including addressing feedback from the 2020 annual shareholder meeting, to ensure that the skills and experience of its directors can effectively support the progress of the Company and the delivery of shareholder value.<\/p>\n<p align=\"justify\">\n        <strong>About Ziopharm Oncology, Inc.<\/strong><br \/>\n        <br \/> Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body\u2019s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm\u2019s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral <em>Sleeping Beauty<\/em> gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured <em>Sleeping Beauty<\/em>-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0wpTVA-A1yWAuBwyMj-kZR4cAuCEhQ4BHL1Es8DDpv7wOYdQwIviX8iFIdKKcqswWUkIi0VQehO1DRWxSjlJuQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ziopharm.com<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements Disclaimer<br \/><\/strong>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; and &#8220;believes.&#8221; These statements include, but are not limited to, statements regarding the growth of Ziopharm from a development-stage entity to a commercial-stage company, development of its clinical portfolio and research and development programs. Although Ziopharm\u2019s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm\u2019s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharm\u2019s intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharm\u2019s Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.<\/p>\n<p>\n        <strong>Investor Relations Contacts:<\/strong><br \/>\n        <br \/> Adam D. Levy, PhD, MBA<br \/> EVP, Investor Relations and Corporate Communications<br \/> T: 508.552.9255<br \/>E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pFLpVTpl-JZJze6UrBATYiQSzYX6vz-qwRPhc71pDMxE_P_Kv1xeIJ1kGlZ8GPGVDeMqpvyxknPSPL_87hQMJPARKIOH6yB6SM5jJVtAYug=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>alevy@ziopharm.com<\/u><\/a><\/p>\n<p>Chris Taylor<br \/> VP, IR and Corporate Communications<br \/> T: 617.502.1881<br \/> E: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zlBt7nCKOg0tWeQ6HhUe8kOci-7i3HBxMDtOpx2Clfri-37exshnqU6FoqK2BJZWsvnMuF-Q8LJuzWT3oEPg8qCWLIBU9VkG20hEaVIUOFk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>ctaylor@ziopharm.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Relations Contact:<br \/><\/strong>LifeSci Communications:<br \/>Patrick Bursey<br \/>T: 646.876.4932<br \/>E: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GuPw2AgpjU2bkriRE1vufpBBIxMdxdzjdjH90Ay2V5wKCBKMPQWw2_wYn3zoN8ULc6dnFotS2ooZJYg6p8VqOpHsBBraOYlvVr7avaqKTpg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">pbursey@lifescicomms.com<\/a><\/u>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/94df8720-dc82-4cf6-a18c-fc81c999ed1e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Special Advisor and Former Chief of Staff for the Bill &amp; Melinda Gates Medical Research Institute Joins as Independent Director \u2013 \u2013 Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership \u2013 \u2013 Scott Braunstein, M.D., Steps Down from Board of Directors \u2013 BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or \u201cthe Company\u201d) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill &amp; Melinda Gates Medical Research Institute, to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Ms. Thistle brings more than 25 years of experience in business development, strategy and operational leadership in the biotechnology sector. At the Bill &amp; Melinda &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ziopharm Oncology Appoints Mary Thistle to Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381705","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Special Advisor and Former Chief of Staff for the Bill &amp; Melinda Gates Medical Research Institute Joins as Independent Director \u2013 \u2013 Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership \u2013 \u2013 Scott Braunstein, M.D., Steps Down from Board of Directors \u2013 BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or \u201cthe Company\u201d) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill &amp; Melinda Gates Medical Research Institute, to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Ms. Thistle brings more than 25 years of experience in business development, strategy and operational leadership in the biotechnology sector. At the Bill &amp; Melinda &hellip; Continue reading &quot;Ziopharm Oncology Appoints Mary Thistle to Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T13:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ziopharm Oncology Appoints Mary Thistle to Board of Directors\",\"datePublished\":\"2020-11-16T13:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/\"},\"wordCount\":1047,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/\",\"name\":\"Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\",\"datePublished\":\"2020-11-16T13:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ziopharm Oncology Appoints Mary Thistle to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk","og_description":"\u2013 Special Advisor and Former Chief of Staff for the Bill &amp; Melinda Gates Medical Research Institute Joins as Independent Director \u2013 \u2013 Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership \u2013 \u2013 Scott Braunstein, M.D., Steps Down from Board of Directors \u2013 BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (\u201cZiopharm\u201d or \u201cthe Company\u201d) (Nasdaq:ZIOP) today announced the appointment of Mary Thistle, Special Advisor for the Bill &amp; Melinda Gates Medical Research Institute, to the Company\u2019s Board of Directors (the \u201cBoard\u201d). Ms. Thistle brings more than 25 years of experience in business development, strategy and operational leadership in the biotechnology sector. At the Bill &amp; Melinda &hellip; Continue reading \"Ziopharm Oncology Appoints Mary Thistle to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T13:33:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors","datePublished":"2020-11-16T13:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/"},"wordCount":1047,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/","name":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=","datePublished":"2020-11-16T13:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjUwNCMzODI4MzgzIzIwMDc1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-oncology-appoints-mary-thistle-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ziopharm Oncology Appoints Mary Thistle to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381705"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381705\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}